Mayo Clinic Zooms in on Nanobacteria.

TAMPA, Fla. -- Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP) announces scientists at Mayo, working under a collaborative agreement with Nanobac Pharmaceuticals Inc., have published an article in the Journal of Investigative Medicine regarding successfully isolating nanoparticles from human kidney stones in cell cultures. The Mayo scientists also isolated proteins, RNA and DNA that appear to be associated with the nanoparticles or CNPs.

Entitled "Mayo Clinic Zooms In On Nanobacteria," the paper describes why the Mayo researchers say the findings could lead to solving the mystery of whether nanoparticles are viable living forms that can lead to disease - in this case, kidney stones. "We are looking at how kidney stones start as very small calcifications inside the kidney and then eventually grow into stones," said Mayo Clinic's John Lieske. "In the laboratory, we have isolated nanoparticles from kidney tissue and kidney stones, and have successfully propagated them in culture. This does not clearly confirm the role of nanoparticles in the formation of kidney stones, but it offers insight not otherwise known."

Intriguingly, the study cites evidence that the calcification process is not driven solely by physical chemistry, but instead is influenced by specific proteins and cellular responses. "There are at least two novel hypotheses here in terms of how stones might actually form. One: an infectious agent. If that was the case, that would point us in the direction of using different kinds of treatments specific to an infectious agent. Two: the idea that cells drive calcification. That would suggest other alternative therapies," added co-researcher Virginia Miller.

Dr. Maniscalco, co-chair of Nanobac, stated, "We believed that CNPs play a major role in one of the most pervasive medical conditions in existence: calcification of arteries and organs. This study conducted by one of the lead medical and research facilities in the United States, lends credence to our beliefs."

About Nanobac Pharmaceuticals: Nanobac Pharmaceuticals, Inc. is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs), formerly known as nanobacteria. The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.